Smith & Nephew (LSE:SN.) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SN. Stoklara Genel Bakış

Smith & Nephew plc, iştirakleri ile birlikte Birleşik Krallık'ta ve uluslararası alanda tıbbi cihazlar ve hizmetler geliştirmekte, üretmekte, pazarlamakta ve satmaktadır.

Şirket hakkında

SN. temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	2/6
Finansal Sağlık	4/6
Temettüler	3/6

Ödüller

Trading at 35.4% below our estimate of its fair value

Earnings are forecast to grow 22.71% per year

Risk Analizi

Dividend of 2.43% is not well covered by earnings or free cash flows

Has a high level of debt

Large one-off items impacting financial results

Smith & Nephew plc Rakipler

NIOX Group

AIM:NIOX

UK£275.6m

ConvaTec Group

LSE:CTEC

UK£4.6b

EKF Diagnostics Holdings

AIM:EKF

UK£134.8m

Mediclinic International

LSE:MDC

UK£3.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Smith & Nephew
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£11.63
52 Haftanın En Yüksek Seviyesi	UK£12.45
52 Haftanın En Düşük Seviyesi	UK£8.87
Beta	0.62
11 Aylık Değişim	-0.64%
3 Aylık Değişim	17.93%
1 Yıllık Değişim	18.60%
33 Yıllık Değişim	-9.35%
5 Yıllık Değişim	-39.17%
Halka arzdan bu yana değişim	5,767.57%

Son Haberler & Güncellemeler

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Sep 25

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Recent updates

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Sep 25

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Aug 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 11

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Aug 19

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Jul 17

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Jun 11

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

May 09

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Apr 09

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

Feb 09

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

Nov 21

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Nov 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Oct 26

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Aug 11

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Jul 28

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 26

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Apr 29

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Safely

Mar 26

Hissedar Getirileri

	SN.	GB Medical Equipment	GB Pazar
7D	1.4%	1.1%	0.1%
1Y	18.6%	11.2%	9.7%

Getiri vs. Endüstri: SN. exceeded the UK Medical Equipment industry which returned 10.1% over the past year.

Getiri vs Piyasa: SN. exceeded the UK Market which returned 8.5% over the past year.

Fiyat Oynaklığı

Is SN.'s price volatile compared to industry and market?
SN. volatility
SN. Average Weekly Movement	3.4%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: SN. has not had significant price volatility in the past 3 months.

Zaman İçindeki Volatilite: SN.'s weekly volatility (3%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1856	18,000	Deepak Nath	www.smith-nephew.com

Smith & Nephew plc, bağlı ortaklıkları ile birlikte Birleşik Krallık'ta ve uluslararası alanda tıbbi cihazlar ve hizmetler geliştirmekte, üretmekte, pazarlamakta ve satmaktadır. Üç segmentte faaliyet göstermektedir: Ortopedi, Spor Hekimliği ve KBB ve Gelişmiş Yara Yönetimi. Şirket, diz replasmanı prosedürleri için diz implantı ürünleri; revizyon prosedürleri için kalça implantları; ciddi kırıkların stabilizasyonunda ve deformite düzeltme prosedürlerinde kullanılan dahili ve harici cihazları içeren travma ve ekstremite ürünleri ve diğer rekonstrüksiyon ürünleri sunmaktadır.

Smith & Nephew plc Temel Bilgiler Özeti

Smith & Nephew'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SN. temel i̇stati̇sti̇kler
Piyasa değeri	UK£10.14b
Kazançlar(TTM)	UK£229.66m
Gelir(TTM)	UK£4.25b

44.2x

F/K Oranı

2.4x

P/S Oranı

SN. aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SN. gelir tablosu (TTM)
Gelir	US$5.64b
Gelir Maliyeti	US$1.67b
Brüt Kâr	US$3.97b
Diğer Giderler	US$3.66b
Kazançlar	US$305.00m

Son Raporlanan Kazançlar

Jun 29, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.35
Brüt Marj	70.33%
Net Kâr Marjı	5.41%
Borç/Özkaynak Oranı	66.7%

SN. uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.4%

Mevcut Temettü Verimi

107%

Ödeme Oranı

SN. güvenilir bir temettü ödüyor mu?

SN. temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman SN. satın almanız gerekir?
Smith & Nephew temettü tari̇hleri̇
Eski Temettü Tarihi	Oct 03 2024
Temettü Ödeme Tarihi	Nov 08 2024
Eski temettüye kadar geçen günler	1 day
Temettü ödeme tarihine kadar geçen günler	37 days

SN. güvenilir bir temettü ödüyor mu?

SN. temettü geçmişine ve kıyaslamalara bakın

SN. Stoklara Genel Bakış

Ödüller

Risk Analizi

Smith & Nephew plc Rakipler

AIM:NIOX

UK£275.6m

LSE:CTEC

UK£4.6b

AIM:EKF

UK£134.8m

LSE:MDC

UK£3.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Consensus EPS estimates fall by 16%

First half dividend of US$0.14 announced

Recent updates

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are

Consensus EPS estimates fall by 16%

First half dividend of US$0.14 announced

First half 2024 earnings: EPS exceeds analyst expectations

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Consensus EPS estimates increase by 11%

Smith & Nephew (LON:SN.) Will Be Hoping To Turn Its Returns On Capital Around

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Consensus EPS estimates fall by 21%

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings: EPS misses analyst expectations

Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Is Smith & Nephew (LON:SN.) Using Too Much Debt?

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Consensus EPS estimates increase by 10%

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Now 22% undervalued

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023